Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc. Common Stock (NY:BHC)

7.790 -0.230 (-2.87%)
Official Closing Price Updated: 4:10 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch Health Companies Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Billionaire Investor Buys Google And This Gold Miner Stock
John Paulson's hedge fund discloses the purchase of 9,000 shares of Alphabet. 
Via Benzinga
Icahn Hedge Fund's Q2 Moves: Centuri Stake Soars, JetBlue Held, 2 Positions Exited
Carl Icahn's 13F shows concentrated equity book, with top 10 holdings making up 98.76%. Notable changes in non-house names like CTRI and IFF. 
Via Benzinga
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
Via ACCESS Newswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Earnings Scheduled For July 30, 2025
 
Via Benzinga
Bausch Health Companies's Earnings Outlook
 
Via Benzinga
Earnings Scheduled For April 30, 2025
 
Via Benzinga
Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners
Via ACCESS Newswire
Bausch Health Announces Second Quarter 2025 Results
Via ACCESS Newswire
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via Phase 3 trials. 
Via Benzinga
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
Via ACCESS Newswire
Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand
Via ACCESS Newswire
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
Via ACCESS Newswire
Bausch Health Appoints New Chief Accounting Officer
Via ACCESS Newswire
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence
Via ACCESS Newswire
Bausch Health to Announce Second Quarter 2025 Results on July 30
Via ACCESS Newswire
GMS Posts Upbeat Earnings, Joins Coinbase Global, Genworth Financial, Sandisk And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Oklo, Quantum Computing And Transocean Are Among Top 10 Mid Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio?
Top mid-cap stocks gain, led by energy companies due to increased oil prices from Middle East conflict. Oklo, Bausch Health, Quantum Computing among top performers. 
Via Benzinga
The Smart Money Is Buying These 10 Stocks
 
Via Benzinga
Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%
Carl Icahn boosts holdings in Illumina and JetBlue, showing confidence in biotech and airlines. He also trims exposure to Southwest Gas Holdings. 
Via Benzinga
Bausch Health Announces 2025 Annual Meeting of Shareholder Results
Via ACCESS Newswire
Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization
Via ACCESS Newswire
Bausch Health Announces First Quarter 2025 Results
Via ACCESS Newswire
Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System
Via ACCESS Newswire
Bausch Health Announces Launch of Solta Medical's Fraxel FTX(TM)
Via ACCESS Newswire
Bausch Health Says Carl Icahn Has 34% Economic Interest In Its Outstanding Shares
This disclosure comes days after the company announced a new “poison pill” plan to safeguard shareholders’ rights and prevent hostile takeovers. 
Via Stocktwits
Bausch Health Announces Filing of Supplement to Proxy Statement
Via ACCESS Newswire
U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich
Via ACCESS Newswire
Bausch Health Announces Adoption of Shareholder Rights Plan
Via ACCESS Newswire
Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.